Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD+ biosynthesis from nicotinamide, exhibit anticancer effects in preclinical models. However, continuous exposure to NAMPT inhibitors, such as FK866, can induce acquired resistance.

Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA / Thongon, Natthakan; Zucal, Chiara; D'Agostino, Vito Giuseppe; Tebaldi, Toma; Ravera, Silvia; Zamporlini, Federica; Piacente, Francesco; Moschoi, Ruxanda; Raffaelli, Nadia; Quattrone, Alessandro; Nencioni, Alessio; Peyron, Jean-Francois; Provenzani, Alessandro. - In: CANCER & METABOLISM. - ISSN 2049-3002. - 6:1(2018), p. 1. [10.1186/s40170-018-0174-7]

Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA

Zamporlini, Federica;Raffaelli, Nadia;
2018-01-01

Abstract

Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD+ biosynthesis from nicotinamide, exhibit anticancer effects in preclinical models. However, continuous exposure to NAMPT inhibitors, such as FK866, can induce acquired resistance.
2018
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/257304
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 27
social impact